TD Waterhouse Canada’s Profound Medical PROF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$902K Buy
143,041
+65,548
+85% +$453K ﹤0.01% 709
2025
Q4
$582K Buy
77,493
+2,200
+3% +$14.1K ﹤0.01% 664
2025
Q3
$356K Buy
75,293
+19,220
+34% +$98.1K ﹤0.01% 757
2025
Q2
$342K Buy
56,073
+14,920
+36% +$78.9K ﹤0.01% 727
2025
Q1
$234K Buy
41,153
+15,751
+62% +$109K ﹤0.01% 761
2024
Q4
$182K Buy
25,402
+1,515
+6% +$11.6K ﹤0.01% 819
2024
Q3
$188K Sell
23,887
-299
-1% -$2.7K ﹤0.01% 784
2024
Q2
$203K Buy
24,186
+8,929
+59% +$72K ﹤0.01% 765
2024
Q1
$166K Sell
15,257
-1,153
-7% -$9.62K ﹤0.01% 804
2023
Q4
$158K Buy
16,410
+15,010
+1,072% +$143K ﹤0.01% 723
2023
Q3
$18.1K Hold
1,400
﹤0.01% 1111
2023
Q2
$23.6K Buy
1,400
+400
+40% +$4.96K ﹤0.01% 1095
2023
Q1
$12.8K Sell
1,000
-270
-21% -$3.12K ﹤0.01% 1173
2022
Q4
$19K Hold
1,270
﹤0.01% 1105
2022
Q3
$6.74K Hold
1,270
﹤0.01% 1296
2022
Q2
$12K Buy
1,270
+270
+27% +$2.13K ﹤0.01% 1212
2022
Q1
$11K Hold
1,000
﹤0.01% 1307
2021
Q4
$13.5K Buy
+1,000
New +$12.5K ﹤0.01% 1286

Other funds holding PROF

TD Waterhouse Canada's PROF Position: Q1 2026 in Review

TD Waterhouse Canada increased its Profound Medical (PROF) stake by 85% in Q1 2026, buying an estimated $453K and bringing the position to 143,041 shares worth $902K. The position accounts for ﹤0.01% of the portfolio, ranked #709.

TD Waterhouse Canada first reported a position in PROF in Q4 2021 and has held it in 18 quarters since. 57 funds tracked by Wall St. Rank hold PROF as of Q1 2026.

  • TD Waterhouse Canada held 143,041 shares of Profound Medical worth $902K as of Q1 2026.
  • TD Waterhouse Canada bought 65,548 Profound Medical shares in Q1 2026, an estimated $453K.
  • Profound Medical made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q1 2026, its #709 holding.
  • TD Waterhouse Canada first reported a position in Profound Medical in Q4 2021 and has held it in 18 quarters since.
  • 57 funds tracked by Wall St. Rank held Profound Medical as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.